The iShares Genomics Immunology and Healthcare ETF (NYSEARCA: IDNA) entered a new phase after one clinical trial readout dramatically altered the fund’s return profile. Moderna, the ETF’s second-largest holding at 6.42%, soared 177.75% to $174.82 in a single session, while Merck, a 4.52% position, rose 12.60% to $152.20.
That combination added roughly 11.98 percentage points to IDNA’s net asset value in one day, an extraordinary outcome for a fund with 65 holdings and about $171 million in assets. The rally pushed the ETF to the top of its 52-week range at $35.42 and underscored how thematic biotech funds can behave more like concentrated event-driven portfolios than diversified sector products.
The subsequent reversal also came quickly. Moderna fell 18.07% to $142.87 in the next session, illustrating how fast a single holding can swing performance once its weight expands inside a passive fund structure.
Key Facts
- IDNA held Moderna at 6.42% and Merck at 4.52% before the Phase 3 trial-driven rally.
- Moderna jumped 177.75% to $174.82 on volume of 182.667 million shares, versus a three-month average of 9.955 million.
- Merck rose 12.60% to $152.20, contributing an estimated 0.57 percentage points to IDNA’s NAV.
- Combined, Moderna and Merck added about 11.98 percentage points of NAV from just 10.94% of the portfolio.
- IDNA’s assets have recently ranged from $160.77 million to $171.44 million, with average daily trading volume of roughly 20,000 to 31,000 shares.
IDNA ETF
IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index and charges a 0.47% net expense ratio. Its portfolio is built to capture long-term growth in genomics, immunology and bioengineering, but the latest move showed that the strategy can become highly sensitive to a handful of clinical-stage or platform biotech names.
The catalyst was positive Phase 3 data for Moderna’s personalized cancer vaccine candidate, intismeran autogene, used with Merck’s KEYTRUDA in melanoma. Because both companies sit near the top of the ETF’s holdings, the same headline boosted two major positions at once. That kind of overlap matters. In biotech and genomics portfolios, a single trial can affect not only one stock but several related companies tied to the same scientific theme, treatment modality or commercial partnership.
For investors, that means the headline count of 65 holdings may overstate diversification. IDNA’s top five holdings account for 27.88% of assets: Revolution Medicines at 7.40%, Moderna at 6.42%, Ipsen at 4.87%, Twist Bioscience at 4.67% and Merck at 4.52%. Several of those businesses are valued more on pipeline potential than on current earnings, making the ETF more exposed to binary trial outcomes, regulatory decisions and changes in risk appetite than a broad healthcare fund.
One successful oncology readout effectively rewrote the risk profile of the entire IDNA ETF in a single session.
Why the concentration increased so quickly
Passive index funds do not need to buy more shares for concentration risk to rise. When one stock jumps sharply, its portfolio weight expands automatically. Based on the size of Moderna’s gain and a roughly 4% rise in the rest of the portfolio, Moderna’s weight likely moved toward about 15.9% after the rally.
That changes the ETF’s mechanics immediately. At a near-16% weight, a 10% move in Moderna would translate into about a 1.6% move in IDNA, while a 20% swing would imply more than 3% of fund performance. When Moderna dropped 18.07% the next day, the hit to NAV was far larger than it would have been before the initial surge.
Implications for Investors
IDNA’s recent performance shows both the opportunity and the risk in thematic biotech investing. Over the past 12 months, the ETF delivered a total return of 69.94%, far above its since-inception average annual return of 6.07% since June 11, 2019. That gap suggests a large share of the recent gain came from a narrow set of catalysts rather than from a broad, steady repricing of the entire portfolio.
Liquidity is another issue worth monitoring. With assets near $171 million and daily turnover often between roughly $700,000 and $1.1 million based on recent volume and price levels, IDNA is not a deeply traded vehicle. Large inflows or outflows can create trading friction, especially because the underlying holdings include volatile biotech names that may have thinner liquidity than large-cap healthcare stocks.
Investors should also watch the next index rebalance. If Moderna’s weight has expanded toward the mid-teens, a scheduled rebalance would mechanically reduce that exposure. That can lower single-stock risk over time, but it may also create forced selling pressure depending on market conditions. In the near term, portfolio behavior is likely to remain heavily influenced by Moderna’s share price, follow-through from the melanoma data, and sentiment toward personalized cancer therapies across the biotech sector.
The broader takeaway is clear: IDNA offers targeted exposure to genomics and immuno-oncology innovation, but it currently carries more concentration risk than its 65-stock label implies. Investors considering the ETF should focus not only on the scientific upside, but also on position sizing, liquidity and the timing of future rebalancing events.
If the melanoma breakthrough leads to wider confidence in individualized neoantigen therapies, IDNA could continue to benefit from a sector-wide rerating. If the initial euphoria fades, the fund’s newly elevated sensitivity to a small number of holdings could make volatility the dominant story.